Frequency of coprescription and potential risk of bronchospasm in Colombian patients users of topical antiglaucomatous betablockers and bronchodilators

Authors

  • Jorge Enrique Machado-Alba Universidad Tecnológica de Pereira
  • Valentina Hoyos-Soto Universidad Tecnológica de Pereira

DOI:

https://doi.org/10.17533/udea.vitae.15590

Keywords:

glaucoma, Pulmonary Disease, Chronic Obstructive, Bronchial Spasm, Adrenergic beta-Antagonists, Adrenergic beta-Agonists, Pharmacoepidemiology, Pharmacovigilance

Abstract

Background: Cardiovascular and respiratory effects of adrenergic agonists used in diseases like chronic obstructive pulmonary disease (COPD), and β-blockers used in glaucoma generate competitive antagonism on the same adrenergic receptor when used simultaneously with the aggravation that the β-blockers can precipitate bronchospasm. Objective: Determine de frequency of coprescription and potential risk of interaction between bronchodilators and topical antiglaucomatous β-blockers for glaucoma in a database of Colombian patients. Methods: Cross-sectional study in patients older than 40 years treated for bronchial disorders and glaucoma between January 1 and October 31, 2012. We used information about 6.2 million population database of individuals enrolled in Health System of Colombia. In the database it was assessed all prescription records of topical β-blockers and any bronchodilators and the frequency of potential risk of developing drug-induced bronchospasm. The identified patients were informed to the physician responsible to the health attention. Results: We found 1756 patients were receiving topical β-blockers and bronchodilators. Most were women (63.2 %), mean age 73.3 ± 11.1 years, in 61 cities. The antiglaucoma drugs more employees were: timolol (67.5 % of patients), timolol/dorzolamide (18.8 % of patients) and bronchodilators: salbutamol (43.8 % of patients) and ipratropium (41.8 % of patients). The more frequent risk associations of bronchospasm were: salbutamol + timolol (n = 890, 50.6 % of patients), ipratropium bromide + timolol (n = 827, 47.1 %) salbutamol + timolol + dorzolamide (n = 258, 14.6 % of patients) and ipratropium bromide + timolol + dorzolamide (n = 255, 14.5 % of patients). Conclusions: The database research of Negative Outcomes Associated with Medication is useful to know problems in prescription of many therapies. There are potential interactions between antiglaucoma drugs and bronchodilators that increase the risk of precipitating bronchospasm in patients who present asthma, COPD and glaucoma in Colombia. Implementing strategies that link drug dispensers and medical insurers can reduce risks associated with the medication.

|Abstract
= 223 veces | PDF
= 78 veces| | PDF (ESPAÑOL (ESPAÑA))
= 16 veces| | REVISTA VITAE
= 0 veces| | CV JORGE MACHADO
= 0 veces| | CV VALENTINA HOYOS
= 0 veces| | FORMATO INFORMACION ARTICULO
= 0 veces|

Downloads

Download data is not yet available.

Author Biographies

Jorge Enrique Machado-Alba, Universidad Tecnológica de Pereira

Director Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia

Valentina Hoyos-Soto, Universidad Tecnológica de Pereira

Semillero de Investigación en Farmacología, Facultad Ciencias de la Salud

References

Centers for Disease Control and Prevention (CDC). Chronic obstructive pulmonary disease among adults--United States, 2011. MMWR Morb Mortal Wkly Rep. 2012; 61 (46): 938-943.

Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008; 133 (2): 343-349.

Gruffydd-Jones K, Loveridge C. The 2010 NICE COPD Guidelines: how do they compare with the GOLD guidelines? Prim Care Respir J. 2011; 20 (2): 199-204.

Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012; 47(4): 171-188.

Rieger-Reyes C, Rubio-Galán FJ. [Glaucoma: Pharmacological implications]. Semergen. 2013; 39 (1): 26-33.

Anonimo. Salud Ocular. Ceguera y pérdida de la visión. [Internet]. Washington (EUA): Organización Panamericana de la Salud, PAHO; 2010. [Actualizado 2010, Jan 11; Consultado: 2012 Sep. 23; Disponible en: http://new.paho.org/chi/index. php?option=com_content&task=view&id=182&Itemid=259

Singh K, Shrivastava A. Medical management of glaucoma: principles and practice. Indian J Ophthalmol. 2011; 59 (Suppl 1): S88-S92

Grupo de investigación en atención farmacéutica (cts-131), Universidad de Granada (España). Tercer Consenso de Granada sobre Problemas Relacionados con Medicamentos (PRM) y Resultados Negativos asociados a la Medicación (RNM). Ars Pharm. 2007; 48 (1): 5-17.

Machado-Alba J, Giraldo C. Ruiz A. Farmacovigilancia de riesgo Cardiovascular por Antiinflamatorios no esteroideos COX-2 selectivos. Rev Investigaciones Andina. 2012; 14 (23): 427-36

Machado-Alba J, Álzate-Carvajal V, Mondragón-Cardona A, Jiménez-Canizales C, Baja frecuencia de prescripción de profilaxis para osteoporosis en pacientes en tratamiento crónico con corticoides en Colombia. Rev Peru Med Exp Salud Pública. 2013; 30 (1): 26-30.

Machado-Alba J, Morales-Plaza C. Prevalencia de interacciones potenciales evitables entre antidepresivos y otros medicamentos en pacientes colombianos. Rev Colomb Psiquiat. 2013; 42 (2): 162-166.

Published

21-07-2014

How to Cite

Machado-Alba, J. E., & Hoyos-Soto, V. (2014). Frequency of coprescription and potential risk of bronchospasm in Colombian patients users of topical antiglaucomatous betablockers and bronchodilators. Vitae, 21(2), 107–113. https://doi.org/10.17533/udea.vitae.15590

Issue

Section

Pharmaceutical Care